Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Diagnostic and Monitoring System for Chronic Kidney Disease Based on Urinary Biomarkers and Preventive Treatment With the SGLT2 Inhibitor Empagliflozin

NCT07348484 is registered in ClinicalTrials.gov with Instituto de Investigación Biomédica de Salamanca as lead sponsor.

NCT NCT07348484
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07348484 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Diagnostic and Monitoring System for Chronic Kidney Disease Based on Urinary Biomarkers and Preventive Treatment With the SGLT2 Inhibitor Empagliflozin
Lead sponsor
Instituto de Investigación Biomédica de Salamanca
Phase
Observational
Overall status
Not yet recruiting
Start date
January 31, 2026
Completion date
March 31, 2028
Enrollment
300 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

chronic kidney disease